Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Summary

The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.

Timeline

Start

2007-05

Primary completion

2010-12

Completion

2011-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications